Key result
Targeting placental VGLL3 protects against preeclampsia and alleviates disease pathology in preclinical models.
Why the study?
Preeclampsia affects approximately 1 in 10 pregnancies with unclear etiology but is linked to autoimmunity and menarche timing.
Does targeting VGLL3 protect against preeclampsia and alleviate disease pathology in preclinical models?
Does targeting VGLL3 protect against preeclampsia and alleviate disease pathology in preclinical models?
VGLL3 is identified as a key upstream regulator in preeclampsia pathogenesis and a promising novel therapeutic target.
Answers are grounded in this paper and cite their sources.
Should not yet change preeclampsia management; leaves open VGLL3 inhibition as hypothesis-generating for clinical trials.
BACKGROUND: Preeclampsia affects approximately 1 in 10 pregnancies, leading to severe complications and long-term health risks for both mother and offspring. While the etiology remains unclear, preeclampsia has been linked to both autoimmunity and the timing of menarche. METHODS: Through human single-cell and spatial analyses, coupled with in vitro, in vivo, and ex vivo models, we demonstrate that VGLL3, a transcription coregulator in the Hippo pathway, is upregulated in preeclamptic placentas. RESULTS: VGLL3 promotes immune activation, impairs trophoblast differentiation, and induces endothelial dysfunction, all of which contribute to pregnancy-related hypertension, fetal growth restriction, and offspring mortality. Our data reveal that VGLL3 acts upstream of preeclampsia-associated processes, including the production of sFLT1 (soluble fms-like tyrosine kinase 1), a key biomarker of the disease. Notably, targeting VGLL3, either by genetic deletion in mouse placentas or through therapeutic inhibition in human placentas, protects against preeclampsia and alleviates disease pathology. CONCLUSIONS: These findings position VGLL3 as a promising novel therapeutic target for preeclampsia.
No takes yet. Share an insight, caveat, or question.
Plazyo et al. (2026) studied Preeclampsia. VGLL3 targeting was evaluated. Targeting VGLL3, which is upregulated in preeclamptic placentas, protected against preeclampsia and alleviated disease pathology in mouse and human models.
Synapse has enriched 10 related papers. Consider them for comparative context: